Oragenics has announced a new license agreement with Inspirevax (formerly Biodextris) for use of Inspirevax’s BDX301 intranasal mucosal adjuvant in Oragenic’s NT-CoV2-1 intranasal COVID-19 vaccine candidate. The company said that the deal includes payments for the achievement of clinical, regulatory and commercial milestones, as well as tiered royalty payments.
In June 2022, Oragenics announced that preclinical data from studies of NT-CoV-2-1 warranted continued development of the vaccine. According to the current announcement, Oragenics and Inspirevax will partner on development of the vaccine going forward and may extend the deal to include additional intranasal vaccine candidates.
Oragenics President and CEO Kimberly Murphy commented, “This agreement represents a major milestone for Oragenics and our corporate strategy initiatives to expand our development opportunities. We are excited to collaborate with the experts at Inspirevax to pursue the development of novel intranasal vaccine candidates. There is an unmet medical need for an intranasal COVID-19 vaccine. We are currently evaluating formulation options for NT-CoV2-1 and assessing various regulatory pathways to advance this program efficiently and thoughtfully. We are working diligently to advance the program and intend to provide an update in mid-2023.”
Inspirevax President and CEO Joseph Zimmermann said, “Intranasally delivered vaccines with our BDX301 adjuvant have shown encouraging results in preclinical models for COVID-19 infections. We welcome the opportunity to partner with Oragenics in the development of a potential novel intranasal vaccine candidate in the global fight against COVID-19 and infectious disease.”
Read the Oragenics press release.
